Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
| ▸ | BCL9 | O00512 | 1/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 4/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.32 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7541194 | 0.82 | HTT (0.33) | PTGS2ALDH1A1NPSR1 | |
| SCHEMBL3943393 | 0.81 | MAPT (0.46) | ALDH1A1NPSR1 | |
| SCHEMBL7535266 | 0.81 | PTPN5 (0.40) | BCL9CTNNB1 | |
| SCHEMBL7536375 | 0.81 | PTGS2 (0.44) | PTGS2ALDH1A1MAOB | |
| SCHEMBL7541985 | 0.78 | IRAK4 (0.38) | ALDH1A1 | |
| SCHEMBL8902496 | 0.75 | MAPK14 (0.39) | PTGS2ALDH1A1NPSR1MAPK14 | |
| SCHEMBL3934774 | 0.69 | HDAC4 (0.45) | ALDH1A1MAOBNPSR1 | |
| SCHEMBL8564127 | 0.69 | KMT2A (0.39) | PTGS2ALDH1A1NPSR1 | |
| SCHEMBL9766788 | 0.69 | MAPT (0.52) | PTGS2TYMPALDH1A1MAPK14 | |
| SCHEMBL12164744 | 0.69 | PTPN5 (0.50) | ALDH1A1MAOAMAOBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013170-B1 | 4-SQUARYLPIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2012-06-27 | — | — | EP | disclosed |
| US-7501419-B2 | 4-Squarylpiperazine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| EP-2013170-A1 | 4-SQUARYLPIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS | Brystol-Myers Squibb Company (US) | 2009-01-14 | — | — | EP | disclosed |
| EP-1895613-A1 | ELECTROLYTE CONTAINING OXOCARBON MOLECULE AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007127731-A1 | 4-SQUARYLPIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070249624-A1 | 4-Squarylpiperazine Derivatives as Antiviral Agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249624-A1 | 4-Squarylpiperazine Derivatives as Antiviral Agents | MAVS, MTAP, SAMHD1 | PTGS2 1835/4885TYMP 5/4885BCL9 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.